SHORT MINI-FUTURE - ELI LILLY & CO | Real-time Boerse Frankfurt Warrants 16:07:38 22/05/2024 BST | ||
| 21.41 EUR | +2.44% |
|
| Current month | -11.63% | ||
| 1 month | -26.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 22/05/24 | 21.41 | +2.44% |
| 21/05/24 | 20.9 | -9.52% |
| 20/05/24 | 23.1 | -3.83% |
| 17/05/24 | 24.02 | +1.56% |
| 16/05/24 | 23.65 | +1.94% |
Real-time Boerse Frankfurt Warrants
Last update May 22, 2024 at 04:07 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD1JJC |
| ISIN | DE000VD1JJC5 |
| Date issued | 05/03/2024 |
| Strike | 1,032 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 22.7 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 28.91 € |
|---|---|
| Lowest since issue | 20.83 € |
| Spread | 0.03 € |
| Spread % | 0.14% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
803.2
USD
Average target price
850.4
USD
Spread / Average Target
+5.88%
- Stock Market
- Certificates
- Certificat
